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ABSTRACT
Background Positron emission tomography (PET) scan
is emerging as a promising imaging technique to detect
large-vessel inﬂammation in giant cell arteritis (GCA).
However, the lack of a standardised deﬁnition of arteritis
based on 18ﬂuorodeoxyglucose (FDG) uptake is an
important limitation to the use of PET scan for diagnostic
purposes.
Objective To prospectively assess the intensity and
distribution of FDG uptake at different vascular territories
in patients with newly diagnosed GCA compared with
controls.
Methods 32 consecutive, biopsy-proven, GCA patients
treated with glucocorticoids for ≤3 days were included.
The control group consisted of 20 individuals, who
underwent PET/CT for cancer staging. Maximal
standardised uptake value (SUVm) was calculated at four
aortic segments, supraaortic branches and iliac-femoral
territory. Sensitivity and speciﬁcity was calculated by
receiver–operator characteristic curves (ROC) analysis.
Results Mean SUVm was signiﬁcantly higher in patients
than in controls in all vessels explored and correlated with
acute-phase reactants and serum IL-6. Mean of the SUVm
at all the vascular territories had an area under the curve
(AUC) of 0.830, and a cut-off of 1.89 yielded a sensitivity
of 80% and a speciﬁcity of 79% for GCA diagnosis.
There were no signiﬁcant differences in AUC among the
vascular beds examined.
Conclusions FDG uptake by large vessels has a
substantial sensitivity and speciﬁcity for GCA diagnosis.
INTRODUCTION
Temporal artery biopsy is the gold standard for the
diagnosis of giant cell arteritis (GCA) due to the
tropism of GCA for the epicranial arteries.1 2 With
a few exceptions,3 histopathological demonstration
of temporal artery inﬂammation provides the most
deﬁnitive evidence of GCA. Doppler ultrasonog-
raphy (DUS) of temporal arteries has emerged as a
useful alternative tool in centres where biopsy is
not easily available.1
The diagnosis of GCA may be also supported by
demonstrating extracranial artery involvement by
imaging. Over the past recent years, positron emis-
sion tomography/CT (PET/CT), CT angiography,
magnetic resonance imaging (MRI) angiography
and DUS have revealed that extracranial involve-
ment in GCA is more frequent than previously
anticipated, occurring in 30–74% of patients.4–7
PET detection of large-vessel involvement in
patients with fever of unknown origin, unexplained
constitutional symptoms or apparently isolated
polymyalgia rheumatica (PMR) has emphasised its
diagnostic potential.8 9 A limitation of PET as a
diagnostic tool is the lack of a standardised deﬁn-
ition of vascular inﬂammation based on the inten-
sity of 18ﬂuorodeoxyglucose (FDG) uptake. While
visual assessment of intensively positive cases may
be clear, there is no consensus about the minimal
intensity of FDG uptake necessary to deﬁne vascu-
lar inﬂammation. Conversely, atherosclerosis and
ageing may increase vascular FDG uptake, poten-
tially leading to vasculitis overdiagnosis.10
In this study, we measured FDG uptake by differ-
ent vascular territories in a cohort of newly diag-
nosed patients and controls and performed
receiver–operator characteristic curves (ROC) ana-
lysis to determine sensitivity and speciﬁcity of FDG
uptake to detect inﬂammation at different vascular
sites. As a secondary endpoint, we analysed poten-
tial correlation between FDG uptake and inﬂamma-
tory biomarkers.
MATERIALS AND METHODS
Patients
Between November 2006 and March 2011, all
patients diagnosed with biopsy-proven GCA2 at our
institution were assessed for potential participation
in the study. Patients who had received glucocortic-
oid treatment for >3 days were excluded. Clinical
and laboratory data recorded are detailed in the
online supplementary methods. The study was
approved by the ethics committee (Hospital Clínic,
Barcelona).
The control group included 20 patients with no
chronic inﬂammatory diseases, matched for gender,
age and cardiovascular risk factors (CVRF), con-
secutively selected among patients who underwent
PET/CT during the same timeframe for early lung
cancer staging.
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PET/CT protocol
PET scans were performed using a hybrid PET/CT (Biograph,
Siemens) with an ECAT EXACT HR+BGO PET and a helicoidal
CT scanner (Somatom, Emotion). Patients fasted 4 h before injec-
tion of 370 MBq of 18F-FDG. Whole-body PET data were
acquired 60 min after in three-dimensional mode and for 5 min
per bed position. PET images were reconstructed both with and
without CT data for attenuation correction. A region of interest
(ROI) in 3-D around the vessel was placed manually in transaxial,
sagittal and coronal slices. The standardised uptake value (SUV)
was calculated based on the measured activity, decay-corrected
injected dose and patient body weight. SUVm=maximal activity
(ROI) (mBq/mL)/injected dose (mBq)/weight (g).
Four aortic segments (ascending thoracic aorta, aortic arch,
descending thoracic aorta and abdominal aorta) and the main
tributaries—carotid, subclavian, axillary, iliac and femoral arter-
ies (each bilaterally)—were evaluated. The control group was
subjected to the same PET/CT protocol. Assessment of PET
data was carried out by two nuclear medicine specialists (FL and
MD), who were blinded to clinical and pathological ﬁndings.
However, unequivocal masked evaluation could not be guaran-
teed due to the controls’ disease.
Statistical analysis
ROC were applied to each vascular territory to calculate sensitivity
and speciﬁcity. Area under the curve (AUC) comparison was per-
formed by Hanley and McNeil analysis. Cut-offs with best sensitiv-
ity and speciﬁcity were selected. Mann–Whitney U test or Student t
test, when applicable, were used for quantitative data. Correlations
were calculated using Pearson’s or Spearman’s test. Statistical signiﬁ-
cance was deﬁned as p<0.05. Calculations were performed with
the IBM SPSS Statistics (V.20.0, Armonk, New York, USA).
RESULTS
Clinical and laboratory ﬁndings of the GCA cohort
Seventy-one GCA patients were diagnosed during the recruit-
ment period. Eight patients refused participation, and 31 had
received glucocorticoid treatment for >3 days. The remaining
32 were included. Seventeen of them had been treated for
≤3 days at the time of imaging. Treatment consisted of oral
prednisone at 1 mg/kg/day. Two patients received 250 mg intra-
venous methylprednisolone pulses (1 and 7 pulses, respectively)
due to severe cranial ischaemic symptoms.
Online supplementary table S1 shows the clinical and labora-
tory data of the study group. There were no relevant differences
in age, gender or CVRF between patients and controls (see
online supplementary table S2).
FDG uptake cut-off for GCA diagnosis
SUVm at any vascular territory explored was signiﬁcantly higher
in GCA patients than in controls (table 1). ROC curves and
AUCs are displayed in ﬁgure 1 and table 1, respectively. Mean
of the SUVm observed at all the vascular territories had an AUC
of 0.830 (0.715–0.946). A cut-off of 1.89 had a sensitivity of
80% and a speciﬁcity of 79%. Mean of the SUVm at supraaortic
vessels showed the highest AUC (0.832). In this site, a cut-off of
1.70 achieved a sensitivity and speciﬁcity of 81 and 79%,
respectively, for the diagnosis of GCA (95% CI 0.720 to 0.946).
FDG uptake at the aorta showed lower AUC (0.738), with a
sensitivity and speciﬁcity of 90 and 42, respectively, using a
cut-off of 2.25, and a sensitivity of 58%, speciﬁcity of 90%
with a cut-off of 2.65 (95% CI 0.598 to 0.881). However, dif-
ferences in AUCs among territories did not reach statistical
signiﬁcance.
Vascular/liver uptake ratios were also signiﬁcantly higher in
patients than in controls at the right axillary and carotid arteries,
Table 1 SUVm and AUC at each vascular bed assessed
Territory GCA patients (mean±SD) Controls (mean±SD) p Value AUC (95% CI)
Ascending aorta 2.63±0.57 2.17±0.26 <0.001 0.778 (0.651 to 0.904)
Aortic arch 2.61±0.50 2.23±0.31 0.002 0.756 (0.621 to 0.891)
Descending thoracic aorta 2.78±0.65 2.39±0.33 0.007 0.739 (0.598 to 0.881)
Abdominal aorta 2.97±0.60 2.56±0.39 0.005 0.748 (0.608 to 0.888)
Right subclavian artery 2.46±0.54 2.14±0.40 0.030 0.763 (0.607 to 0.889)
Left subclavian artery 2.26±0.56 1.89±0.28 0.003 0.764 (0.610 to 0.891)
Right carotid artery 2.33±0.52 1.83±0.25 <0.001 0.812 (0.695 to 0.930)
Left carotid artery 2.32±0.51 1.97±0.30 0.004 0.733 (0.594 to 0.872)
Right axillary artery 1.21±0.31 0.88±0.17 <0.001 0.830 (0.725 to 0.940)
Left axillary artery 1.09±0.34 0.88±0.18 0.001 0.780 (0.627 to 0.886)
Right iliac artery 2.41±0.67 2.01±0.38 0.009 0.747 (0.606 to 0.888)
Left iliac artery 2.46±0.47 2.00±0.41 0.002 0.767 (0.628 to 0.905)
Right femoral artery 1.68±0.39 1.24±0.22 <0.001 0.817 (0.715 to 0.928)
Left femoral artery 1.50±0.37 1.14±0.18 <0.001 0.801 (0.679 to 0.922)
All territories* 2.15±0.37 1.79±0.17 <0.001 0.830 (0.715 to 0.946)
Aorta** 2.75±0.54 2.34±0.23 0.001 0.738 (0.612 to 0.874)
Supraaortic branches** 1.95±0.35 1.59±0.15 <0.001 0.832 (0.732 to 0.968)
Iliofemoral territory** 1.97±0.36 1.62±0.23 <0.001 0.802 (0.679 to 0.925)
Liver 2.76±0.57 2.52±0.42 0.119 0.635 (0.480 to 0.790)
Removal of the two patients who had received intravenous methylprednisolone pulses at the time of PET performance did not significantly modify the results (data not shown).
Differences in AUCs among different vascular territories did not reach statistical significance.
AUC, area under the curve; GCA, giant cell arteritis; PET, positron emission tomography.
*Values represent the mean of the SUVm observed at all the vascular beds assessed.
**Aorta, Supraaortic branches and Iliofemoral territory represents the mean of the SUVm observed at the different vessels of these areas.
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but the overall discriminatory performance was much lower (see
online supplementary table S3).
Relationship between FDG uptake and clinical
and laboratory ﬁndings
Patients with cranial symptoms presented signiﬁcantly higher
values of maximal and mean SUVm (combined average of all vas-
cular territories) than patients lacking cranial manifestations. No
relationship between the intensity of FDG uptake and other clin-
ical ﬁndings was observed (table 2). No differences in maximal
or mean SUVm were observed between treatment-naïve patients
and those who had received glucocorticoids. The maximal and
mean SUVm correlated with acute-phase reactants and serum
IL-6 concentrations (table 2).
DISCUSSION
The present prospective study, performed in an unselected
patient cohort with unequivocal GCA, shows that FDG uptake is
signiﬁcantly stronger in patients than in controls in all vascular
territories tested, conﬁrming the diagnostic potential of PET/
CT.4 8 9 11 PET/CTallows rapid, reproducible and broad vascular
evaluation. Nevertheless, there is no standardised deﬁnition of
vasculitis based on an objective FDG uptake measure, and strat-
egies employed to establish a PET-based diagnosis of GCA has
been heterogeneous. Most studies have used qualitative visual
assessment or a semiquantitative score using liver uptake as a ref-
erence. Visual scoring has a remarkable investigator dependency
and interobserver variability. Liver uptake is inﬂuenced by indi-
vidual metabolic activity, glucocorticoid treatment and the time
lapse between injection and scanning.12
We tried to overcome this limitation by objectively quantifying
FDG uptake by different vascular beds in patients and controls
and performing ROC analysis to determine the optimal cut-off
for GCA diagnosis at different vascular territories. FDG uptake
by supraaortic branches had the highest AUC, in accordance with
a pioneer study showing that supraaortic branches were the most
frequently involved when assessed by PET.4 In this area, an FDG
uptake cut-off value of 1.70 had the best sensitivity and speciﬁ-
city. A similar value, in the same territory but with lower per-
formance (AUC=0.72), was reported in a retrospective study of
17 patients with GCA and 3 Takayasu arteritis patients.13 This
observation may be useful to differentiate GCA from other
inﬂammatory aortic diseases that may produce systemic com-
plaints and active aortic FDG uptake, including idiopathic aorti-
tis, periaortitis, IgG4 disease and severe atherosclerosis.10 14–17
This is crucial since a positive PET/CT may be accepted in the
near future as a diagnostic criterion and is currently accepted as
such in an ongoing clinical trial with tocilizumab in GCA.18
Figure 1 Receiver–operator characteristic curves of standardised uptake value at different vascular regions.
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The sensitivity and speciﬁcity of PET/CT obtained in this
study is close to that calculated in a recent systematic review/
meta-analysis of heterogeneous, mostly retrospective studies,
and those reported in a retrospective analysis evaluating the
impact of PET on the management of patients with suspected
large-vessel vasculitis.19
Interestingly, FDG uptake by the aorta showed a lower AUC,
being worse in the abdominal segment where atherosclerosis is
more prevalent in the general population. This fact highlights
the diagnostic limitation of PET in this territory since aortic
FDG uptake may be markedly inﬂuenced by ageing or atheroma
plaques. Hautzel et al reported a higher sensitivity and speciﬁ-
city of thoracic aorta FDG uptake to detect large-vessel inﬂam-
mation in a cohort of 18 patients with GCA.20 A thoracic aorta/
liver ratio of 1.0 had a sensitivity and speciﬁcity of 88% and
93%, respectively (AUC = 0.932). However, a substantial pro-
portion of the patients assembled in this cohort were selected
on the basis of previously known large-vessel involvement
demonstrated by other techniques. In our study, direct, territory-
focused comparison of SUVm between patients and controls dis-
criminated better than vascular/liver ratios.
A retrospective study evaluating how PET/CT results inﬂu-
enced management of patients with suspected GCA suggested
that previous glucocorticoid (GC) treatment decreased the diag-
nostic yield of PET/CT.19 Sequential assessments have demon-
strated, indeed, that FDG uptake decreases after 3 months of
treatment.4 The present study suggests that a short course of
therapy (≤3 days) may not substantially reduce the diagnostic
accuracy of PET/CT.
In conclusion, this study provides sensitive and speciﬁc,
territory-focused cut-off values to detect vascular inﬂammation
by PET/CT. A limitation of the study is that while patients were
prospectively recruited, controls were retrospectively selected.
Another limitation is the relatively small number of patients ana-
lysed, although our cohort is among the largest investigated.
Further prospective studies using objective cut-offs are necessary
to conﬁrm their diagnostic performance in patients with sus-
pected GCA.
Author afﬁliations
1Vasculitis Research Unit, Department of Systemic Autoimmune Diseases, Hospital
Clínic, University of Barcelona, Institut d’Investigacions Biomèdiques August Pi i
Sunyer (IDIBAPS), Barcelona, Spain
2Center for Diagnostic Imaging, Hospital Clínic, University of Barcelona, Institut
d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
3Department of Emergency Medicine, Hospital Clínic, University of Barcelona, Institut
d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
4Department of Internal Medicine, Hospital Clínic, University of Barcelona, Institut
d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Contributors MCC had full access to all of the data in the study and takes
responsibility for the integrity of the data and the accuracy of the data analysis.
Study design: SP-G, FL and MCC. Acquisition of data: SP-G, MD, AG-M, GE-F, IT-B,
FL, MC-B, EP-R, MAA, JMG, JH-R and MCC. Analysis and interpretation of data:
SP-G, MD, GE-F, FL, JH-R and MCC. Manuscript preparation: SP-G, FL, JH-R, JMG
and MCC. Statistical analysis: SP-G, MAA, MCC.
Competing interests Supported by Ministerio de Economía y Competitividad
(SAF 08/04328 and SAF11/30073). SP-G was a postresidency research award
recipient from Hospital Clínic. MAA was supported by Consejo Nacional de Ciencia y
Tenología (CONACyT), Mexico, and by Agencia de Gestió d’Ajuts Universitaris i de
Recerca (AGAUR), Generalitat de Catalunya.
Ethics approval The study was approved by the ethics committee of our
institution (Hospital Clínic, Barcelona).
Provenance and peer review Not commissioned; externally peer reviewed.
REFERENCES
1 Salvarani C, Pipitone N, Versari A, et al. Clinical features of polymyalgia rheumatica
and giant cell arteritis. Nat Rev Rheumatol 2012;8:509–21.
2 Lie JT. Illustrated histopathologic classiﬁcation criteria for selected vasculitis
syndromes. American College of Rheumatology Subcommittee on Classiﬁcation of
Vasculitis. Arthritis Rheum 1990;33:1074–87.
3 Esteban MJ, Font C, Hernandez-Rodriguez J, et al. Small-vessel vasculitis
surrounding a spared temporal artery: clinical and pathological ﬁndings in a series
of twenty-eight patients. Arthritis Rheum 2001;44:1387–95.
4 Blockmans D, de Ceuninck L, Vanderschueren S, et al. Repetitive
18F-ﬂuorodeoxyglucose positron emission tomography in giant cell arteritis:
a prospective study of 35 patients. Arthritis Rheum 2006;55:131–7.
5 Prieto-Gonzalez S, Arguis P, Garcia-Martinez A, et al. Large vessel involvement in
biopsy-proven giant cell arteritis: prospective study in 40 newly diagnosed patients
using CT angiography. Ann Rheum Dis 2012;71:1170–6.
6 Schmidt WA, Seifert A, Gromnica-Ihle E, et al. Ultrasound of proximal upper
extremity arteries to increase the diagnostic yield in large-vessel giant cell arteritis.
Rheumatology (Oxford) 2008;47:96–101.
7 Aschwanden M, Kesten F, Stern M, et al. Vascular involvement in patients with
giant cell arteritis determined by duplex sonography of 2×11 arterial regions. Ann
Rheum Dis 2010;69:1356–9.
8 Hao R, Yuan L, Kan Y, et al. Diagnostic performance of 18F-FDG PET/CT in patients
with fever of unknown origin: a meta-analysis. Nucl Med Commun 2013;
34:682–8.
9 Blockmans D, De Ceuninck L, Vanderschueren S, et al. Repetitive 18-ﬂuorodeoxyglucose
positron emission tomography in isolated polymyalgia rheumatica: a prospective study in
35 patients. Rheumatology (Oxford) 2007;46:672–7.
10 Dunphy MP, Freiman A, Larson SM, et al. Association of vascular 18F-FDG uptake
with vascular calciﬁcation. J Nucl Med 2005;46:1278–84.
Table 2 Relationship between clinical and laboratory data and maximal SUV at any vascular territory (SUVm) and mean of the SUVm obtained
at every vascular bed assessed (mean SUVm).
Maximal SUVm Mean SUVm
p Value p Value
Cranial symptoms (P/A) 3.21±0.65/2.50±0.52 0.021 2.24±0.32/1.77±0.36 0.004
Systemic symptoms (P/A) 3.12±0.61/2.98±0.82 0.589 2.20±0.35/2.07±0.43 0.354
Ischaemic symptoms (P/A) 2.91±0.61/3.14±0.71 0.402 2.11±0.39/2.17±0.37 0.708
PMR (P/A) 3.11±0.62/3.06±0.71 0.886 2.27±0.35/2.12±0.38 0.321
GC treatment (Y/N) 2.97±0.44/3.20±0.81 0.385 2.14±0.36/2.17±0.40 0.858
CRP, mg/dL r=0.551 0.001 r=0.476 0.034
ESR, mm/h r=0.442 0.011 r=0.335 0.050
Haptoglobin, mg/dL r=0.585 0.008 r=0.358 0.050
IL-6, pg/mL r=0.616 0.002 r=0.544 0.007
Values are mean±SD.
Removal of the two patients who had received intravenous methylprednisolone pulses at the time of PET performance did not substantially modify the results (data not shown).
A, absence; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; F, female; GC, glucocorticoid; IL-6, interleukin 6; M, male; N, no; NS, not significant; P, presence; PET, positron
emission tomography; PMR, polymyalgia rheumatica; SUV, standardized uptake value; Y, yes.
Prieto-González S, et al. Ann Rheum Dis 2014;73:1388–1392. doi:10.1136/annrheumdis-2013-204572 1391
Clinical and epidemiological research
group.bmj.com on April 19, 2017 - Published by http://ard.bmj.com/Downloaded from 
11 Besson FL, Parienti JJ, Bienvenu B, et al. Diagnostic performance of (1)
F-ﬂuorodeoxyglucose positron emission tomography in giant cell arteritis:
a systematic review and meta-analysis. Eur J Nucl Med Mol Imaging
2011;38:1764–72.
12 Iozzo P, Geisler F, Oikonen V, et al. Insulin stimulates liver glucose uptake in
humans; an 18F-FDG uptake in humans. J Nucl Med 2003;
44:682–9.
13 Lehmann P, Buchtala S, Achajew N, et al. 18F-FDG PET as a diagnostic procedure
in large vessel vasculitis-a controlled, blinded re-examination of routine PET scans.
Clin Rheumatol 2011;30:37–42.
14 Reeps C, Essler M, Pelisek J, et al. Increased 18F-ﬂuorodeoxyglucose uptake in
abdominal aortic aneurysms in positron emission/computed tomography is
associated with inﬂammation, aortic wall instability, and acute symptoms. J Vasc
Surg 2008;48:417–23.
15 Salvarani C, Pipitone N, Versari A, et al. Positron emission tomography (PET):
evaluation of chronic periaortitis. Arthritis Rheum 2005;53:298–303.
16 Vaglio A, Catanoso MG, Spaggiari L, et al. IL6 as an inﬂammatory mediator and
target of therapy in chronic periaortitis. Arthritis Rheum 2013;65:2469–75.
17 Vaglio A, Salvarani C, Buzio C. Retroperitoneal ﬁbrosis. Lancet 2006;
367:241–51.
18 Unizony SH, Dasgupta B, Fisheleva E, et al. Design of the tocilizumab in giant cell
arteritis trial. Int J Rheumatol 2013;2013:912562.
19 Fuchs M, Briel M, Daikeler T, et al. The impact of 18F-FDG PET on the
management of patients with suspected large vessel vasculitis. Eur J Nucl Med Mol
Imaging 2012;39:344–53.
20 Hautzel H, Sander O, Heinzel A, et al. Assessment of large-vessel involvement in
giant cell arteritis with 18F-FDG PET: introducing an ROC-analysis-based cutoff
ratio. J Nucl Med 2008;49:1107–13.
1392 Prieto-González S, et al. Ann Rheum Dis 2014;73:1388–1392. doi:10.1136/annrheumdis-2013-204572
Clinical and epidemiological research
group.bmj.com on April 19, 2017 - Published by http://ard.bmj.com/Downloaded from 
control study−arteritis: a prospective, case
 newly diagnosed, biopsy-proven giant cell
 of large vessel inflammation in patients with
 Positron emission tomography assessment
Franciso Lomeña and Maria C Cid
Planas-Rigol, Marco A Alba, José Hernández-Rodríguez, Josep M Grau,
Espígol-Frigolé, Itziar Tavera-Bahillo, Marc Corbera-Bellata, Ester 
Sergio Prieto-González, Marina Depetris, Ana García-Martínez, Georgina
doi: 10.1136/annrheumdis-2013-204572
2014
2014 73: 1388-1392 originally published online March 24,Ann Rheum Dis 
 http://ard.bmj.com/content/73/7/1388
Updated information and services can be found at: 
These include:
Material
Supplementary
 72.DC1
http://ard.bmj.com/content/suppl/2014/03/24/annrheumdis-2013-2045
Supplementary material can be found at: 
References
 #BIBLhttp://ard.bmj.com/content/73/7/1388
This article cites 19 articles, 7 of which you can access for free at: 
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (1367)Epidemiology
 (1251)Inflammation
 (294)Vascularitis
 (750)Radiology (diagnostics)
 (1113)Radiology
 (5144)Immunology (including allergy)
 (1282)Clinical diagnostic tests
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on April 19, 2017 - Published by http://ard.bmj.com/Downloaded from 
